Clinical trials: NAD
Covid19, Stage 1 Acute Kidney Injury
Phase 2a MIB-626 vs. Placebo COVID-19
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by…
- Trial name
- NCT05038488
- Testing
- MIB-626, Home Treatment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Metro International Biotech, LLC
Sarcopenia, Nicotinamide Adenine Dinucleotide Concentration
Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans
Frailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality.
- Conditions
- Sarcopenia, Nicotinamide Adenine Dinucleotide Concentration, Muscle Quality and NAD+ Content
- Trial name
- NR-VET (NCT04691986)
- Testing
- Nicotinamide Riboside
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Lung Cancer
Study of Weekly Paclitaxel, Carboplatin and Irinotecan to Treat Lung Cancer
Evaluate the efficacy and toxicity of the weekly combination chemotherapy of Paclitaxel, Carboplatin and Irinotecan in Stage IIIb and IV NSCLC with malignant pleural effusion
- Trial name
- NCT00465907
- Testing
- Paclitaxel, Carboplatin and Irinotecan
- Where
- Singapore
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Healthy
NAD-brain: a Pharmacokinetic Study of NAD Replenishment Therapy
The objective of the NAD-brain study is to determine the blood and brain pharmacokinetics of NAD replenishment therapy (NRT) using Nicotinamide Riboside (NR) or Nicotinamide Mononucleotide (NMN).
- Trial name
- NAD-brain (NCT05698771)
- Testing
- Nicotinamide Riboside (NR), nicotinamide mononucleotide
- Where
- Norway
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Heart Failure
The Effect of Nicotinamide Riboside on Skeletal Muscle Function in Heart Failure Subjects
Background: People are living longer and are more likely to survive a heart attack if they have one. Longer life expectancy is good but it also means more people get chronic heart failure over time.
- Trial name
- NCT03565328
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Lymphoblastic Leukemia, Cancer Survivors
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.
- Conditions
- Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes
- Trial name
- IAMFIT (NCT05194397)
- Testing
- Nicotinamide Riboside, Exercise Intervention
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Children's Hospital of Philadelphia
Multiple Sclerosis
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed…
- Trial name
- REPAIR-MS (NCT03993171)
- Testing
- gold nanocrystals
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Clene Nanomedicine
Covid19, Sequelae of; Infection
Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
The study will assess whether Niagen, a safe dietary supplement, improves recovery of COVID-19 related symptoms in individuals who were infected at least 2 months prior to study entry ("Long-COVID" "Long-haulers").
- Conditions
- Covid19, Sequelae of; Infection, Cognitive Symptom
- Trial name
- NCT04809974
- Testing
- Niagen
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
Parkinson Disease
A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease
NOPARK is a double-blinded randomized controlled phase II trial, with the aim to assess the efficacy of nicotinamide adenine dinucleotide (NAD)-replenishment therapy in the form of oral nicotinamide riboside (NR) in delaying the…
- Trial name
- NOPARK (NCT03568968)
- Testing
- Nicotinamide Riboside
- Where
- 11 sites in Norway
- Volunteers
- 410 people
- Sponsor
- Haukeland University Hospital
Systemic Lupus Erythematosus (Sle)
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness.
- Trial name
- NCT06032923
- Testing
- Nicotinamide Riboside
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Alzheimer Disease, Dementia
N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease
The goal of this double-blinded placebo-controlled randomized trial is to determine the optimal dose of nicotinamide riboside (NR), in individuals with Alzheimer's disease (AD).
- Trial name
- NCT05617508
- Testing
- Nicotinamide Riboside supplementation 1000mg daily in total, Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)
- Where
- 2 sites in Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Healthy Adults
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
We are doing this research to learn how healthy younger and older adults use two forms of vitamin B3-called nicotinamide mononucleotide (NMN) and nicotinamide (NAM)-to make NAD+.
- Trial name
- NCT06882096
- Testing
- Nicotinamide Mononucleotide (NMN), Nicotinamide (NAM)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Metro International Biotech, LLC
Metabolic Syndrome, Premature Aging
The Safety and Efficacy Study of RiaGev in Healthy Adults
This current randomized, double-blind, comparator-controlled, cross over study investigates the efficacy and safety of RiaGev™ via evaluation of NAD+, ATP, glucose, insulin, glutathione, and cortisol levels in healthy adults of…
- Trial name
- NCT04483011
- Testing
- RiaGev
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bioenergy Life Science, Inc.
Peripheral Artery Disease
NAD Supplementation and Vascular Health in PAD
This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older…
- Trial name
- NCT06534944
- Testing
- Nicotinamide riboside
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Oklahoma
Health Adult Subjects, Healthy Participants
Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort
The goal of this 5 day interventional study was to investigate the effects on multiple biological molecules (multi-omics) of Bryleos's commercially available oral LathMized™ Nicotinamide adenine dinucleotide (LNAD+) supplement in…
- Trial name
- Renewal-NAD+ (NCT07336836)
- Testing
- LathMized TM NAD+ (LNAD+)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BioNADrx Holdings, Inc. Bryleos
Parkinson Disease
NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease
NR-SAFE is a double-blinded randomized safety study aiming to determine the safety and tolerability of nicotinamide riboside (NR) at a daily dose of 3000mg, in individuals with Parkinson's disease (PD).
- Trial name
- NR-SAFE (NCT05344404)
- Testing
- Nicotinamide Riboside
- Where
- Norway
- Volunteers
- 20 people
- Sponsor
- Haukeland University Hospital
IFN-Gamma Therapy, CGD Gene Mutation
Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
Background: Chronic granulomatous disease (CGD) is an immunodeficiency disease in which white blood cells are unable to kill certain bacteria and fungi.
- Conditions
- IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease
- Trial name
- NCT01147042
- Testing
- IFN-gamma
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Depression
European Comparative Effectiveness Research on Internet-based Depression Treatment in Poland
Effective, accessible, and affordable depression treatment is of high importance considering the large individual and economic burden of depression.
- Trial name
- E-COMPARED (NCT02389660)
- Testing
- Blended Cognitive Behavioural Therapy (CBT), Treatment as usual
- Where
- Poland
- Volunteers
- 84 people
- Sponsor
- University of Social Sciences and Humanities, Warsaw
Solid Tumor, Non Small Cell Lung Cancer
NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC
This is a phase I, single center (West China Hospital, Sichuan University) study aimed at investigating the safety and efficacy of NMN supplements combined with chemotherapy and radiation therapy for second-line and above…
- Trial name
- NMN (NCT06966583)
- Testing
- NAD supplement, Radiotherapy, Immunotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Concussion, Mild
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as measured by 31P MRS?
- Trial name
- TRMC-004 (NCT02721537)
- Testing
- Nicotinamide Riboside
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic